Talphera (TLPH) Return on Capital Employed (2011 - 2026)
Talphera's (TLPH) quarterly Return on Capital Employed came in at 56.02% in Q1 2026, up 3922.0% year-on-year from 1.39% in Q1 2025, and down 9.77% quarter-over-quarter from 51.03% in Q4 2025.
Talphera (TLPH) Return on Capital Employed (2011 - 2026) Analysis & Trends
Talphera's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 56.02% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 3922.0% year-over-year to 56.02% in Q1 2026; TTM through Mar 2026 was 56.02%, a 3922.0% increase from a year earlier, with the FY2025 full-year figure at 66.86%, up 2465.0% from the prior year.
- Return on Capital Employed slipped to 56.02% in Q1 2026 per TLPH's latest filing, from 51.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 51.03% in Q4 2025 and bottomed at 101.74% in Q2 2025.
- The 5-year median for Return on Capital Employed is 77.13% (2022), against an average of 76.36%.
- Across the five-year window, Return on Capital Employed sank 3335 bps in 2025 and soared 3922 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 86.02% in 2022, then gained by 21 bps to 67.98% in 2023, then plunged by 32 bps to 89.83% in 2024, then surged by 43 bps to 51.03% in 2025, then fell by 10 bps to 56.02% in 2026.
- Per Business Quant, the three latest TLPH Return on Capital Employed figures stand at 56.02% (Q1 2026), 51.03% (Q4 2025), and 63.81% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | -56.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.02% |
| Dec 31, 2025 | -51.03% |
| Sep 30, 2025 | -63.81% |
| Jun 30, 2025 | -101.74% |
| Mar 31, 2025 | -95.24% |
| Dec 31, 2024 | -89.83% |
| Sep 30, 2024 | -81.99% |
| Jun 30, 2024 | -68.39% |
| Mar 31, 2024 | -74.38% |
| Dec 31, 2023 | -67.98% |
| Sep 30, 2023 | -79.05% |
| Jun 30, 2023 | -82.01% |
| Mar 31, 2023 | -75.02% |
| Dec 31, 2022 | -86.02% |
| Sep 30, 2022 | -86.54% |
| Jun 30, 2022 | -77.13% |
| Mar 31, 2022 | -61.86% |
| Dec 31, 2021 | -63.58% |
| Sep 30, 2021 | -62.92% |
| Jun 30, 2021 | -54.83% |